Table 3. Patient Characteristics Are Compared With Outcome.
| MBq infused | Age (y) | No. of Chemotherapy regimens* | Ascites | Largest tumor (cm) (includes nodes) | No. of masses > 1 cm | HER-2 immuno-histochemistry score | ELISA | Response 6 wk | Mo. Since treatment |
|---|---|---|---|---|---|---|---|---|---|
| 15 | 46 | 5 | limited | 3.4 | 5 | 2+; >30% | 10.3 | S | 9† |
| 11 | 67 | 5 | limited | 2.8 | 5 | 1+; >30% | N/A | S | 24 |
| 11 | 83 | 3 | large | 4 | 2 | 2+; >30% | 9.6 | P | 14† |
| 13 | 60 | 3 | 0 | 1.8 | 5 | 1+; >30% | 12.3 | S | 18 |
| 17 | 62 | 1 | 0 | 2.5 | 3 | 2+; >30% | 13.7 | P | 2† |
| 21 | 77 | 2 | large | 2.9 | 1 | 1+; <10% | 14.6 | P | 2† |
| 21 | 66 | 9 | 0 | 2.6 | 4 | 1+; >30% | 12.3 | S | 11† |
| 19 | 59 | 4 | 0 | 4.3 | 3 | 1+; >30% | 14.7 | S | 14 |
| 25 | 80 | 2 | 0 | 7.2 | 5 | 1+; >10% | 13.7 | S | 4† |
| 19 | 71 | 3 | 0 | ne | 0 | 1+; >30% | 12.2 | S | 11 |
| 31 | 54 | 8 | 0 | 3.9 | 4 | 1+; >30% | N/A | S | 9 |
| 28 | 68 | 5 | 0 | 4.5 | 2 | N/A | 16.4 | P | 9 |
| 31 | 72 | 2 | large | 5.1 | 5 | 1+; >30% | 18.9 | S | 8 |
| 39 | 59 | 4 | limited | 1.2 | 3 | 1+; >30% | 15.2 | S | 5 |
| 40 | 73 | 2 | 0 | 1.5 | 1 | 2+; >10% | N/A | S | 4 |
| 38 | 61 | 1 | 0 | 1.3 | 2 | 1+; >30% | 9.2 | S | 4 |
*
Number of chemotherapy cycles ranged from 6 to 64. Most common regimens contained taxane or platinum, followed by anthracycline, gemcitabine, and topotecan as cytotoxic chemotherapy. Some regimens included bevacizumab, other antibody, vaccine, molecularly targeted inhibitor, or adenoviral vector therapy. Hormonal agents were not considered as regimens.
†
Deaths.
S = stable; P = disease progression; NA = not applicable.